Latest News
More than half of human cancers, called “non-inflamed” or “cold” tumors, are not being effectively infiltrated by the cancer-fighting T cells. Essentially, the soldiers are excluded from the battlefield. Yale Cancer Center researchers want to know why.
- November 28, 2023
The Yale Advanced Diagnostic Tests Laboratory in the Department of Pathology, a new unit of Yale Pathology Laboratories, offers access to novel molecular tests to external users, performing and interpreting clinical grade and high-quality molecular analysis of human tissue samples.
- January 18, 2023
In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell lung cancer (NSCLC). We’ll be hearing from Professor Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, Dr Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, and Dr Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, about new developments in our understanding of mechanisms of resistance, as well as possible therapeutic options for overcoming resistance.
- January 10, 2023
Yale Cancer Center's Class of 1961 Cancer Research Awards were presented to Nikhil Joshi, PhD, and Kurt Schalper, MD, PhD, at the annual Yale Cancer Center Conclave on January 5, 2023.
- December 01, 2022Source: Bioanalysis Zone
As the world continues to grapple with the COVID-19 pandemic, we gathered experts from different disciplines to discuss the emergence of novel variants of concern and the development of cell and gene therapies, both in the past and throughout the COVID-19 pandemic.
- November 28, 2022Source: VuMedi
TAP2 Deficiency Mediates Adaptive Immune Evasion and Immunotherapy Resistance in Human NSCLC
- November 10, 2022
Kishu Ranjan, PhD, of Yale University School of Medicine, discusses his study findings, which identified a deficiency in the biomarker TAP2 as a prominent immune evasion mechanism in patients whose non–small cell lung cancer has resisted immunotherapy.
- October 27, 2022Source: VJOncology
Downregulation of TAP2 and to a lesser extent, TAP1, have been found to increase immune evasion in tumors. Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, discusses the clinical implications and future research potential for these findings. Elucidating additional mutations in TAP1/2, novel molecular targets such as RBBP7 and epigenetic modulators are crucial to exploit TAP1/2 downregulation to increase PD-L1 inhibitor efficacy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
- September 22, 2022Source: UNIVISION
Este 22 de septiembre el Instituto de Investigación del Cáncer en Estados Unidos llevará a cabo una conferencia virtual en la que abordará varios temas sobre la inmunoterapia y sus beneficios para los pacientes con cáncer. De acuerdo con Kurt Schalper, profesor de la Universidad de Yale, el objetivo de dicha reunión es lograr que la comunidad hispana tenga acceso a información valiosa acerca de dicho tratamiento. | This September 22, the Institute for Cancer Research in the United States will hold a virtual conference in which it will address various topics about immunotherapy and its benefits for cancer patients. According to Kurt Schalper, a professor at Yale University, the objective of this meeting is to ensure that the Hispanic community has access to valuable information about said treatment.
- September 06, 2022Source: PR Newswire
The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system's power to control and potentially cure all cancers, will offer its second annual CRI Virtual Immunotherapy Patient Summit in Spanish on September 22, 2022, 2-5 p.m. ET. This free virtual event, moderated by TV Host and Entrepreneur Ana Patricia Gámez, and presented completely in Spanish, will connect Hispanic cancer patients and caregivers with groundbreaking research updates from leading immunotherapy experts driving scientific breakthroughs and advancements that impact patient care.